Loading field map
Health Technology Assessment (HTA) is a multidisciplinary field that systematically evaluates the properties, effects, and impacts of health technologies. It is a form of policy-oriented research that informs decisions about whether and under what conditions a health technology should be adopted, used, or reimbursed within a healthcare system. The term "health technology" is broad, encompassing drugs, medical devices, diagnostic tests, surgical procedures, public health programs, and organizational or support systems used in healthcare.
The central questions of HTA are practical and consequential. They include: Does this technology work better than existing alternatives? For whom? At what cost? Is it worth the resources it consumes compared to other ways of using those resources? What are the broader social, ethical, and organizational implications of its use?
The stakes are high. Healthcare systems face rising costs, aging populations, and constant pressure from new technologies. HTA provides evidence to help allocate limited resources efficiently and equitably. Its findings can determine whether a new cancer drug is covered by public insurance, whether a screening program is expanded, or whether a surgical device is adopted in public hospitals. Because these decisions affect patient access, industry revenues, and public budgets, HTA is a site of intense methodological debate and political negotiation.
HTA emerged in the 1970s, primarily in the United States and Europe, as a response to the rapid proliferation of medical technologies and growing concerns about their costs, safety, and effectiveness. The field drew on earlier traditions of technology assessment in engineering and environmental policy, but adapted them to healthcare. The U.S. Office of Technology Assessment (OTA), established in 1972, conducted early influential studies, though it was not exclusively focused on health. In Europe, countries like Sweden and the Netherlands developed formal HTA programs in the 1980s, often linked to national health insurance systems.
The field grew rapidly in the 1990s and 2000s as governments sought systematic ways to control costs while maintaining quality. The establishment of the UK's National Institute for Health and Care Excellence (NICE) in 1999 was a landmark, creating a high-profile institution that explicitly used cost-effectiveness analysis to guide coverage decisions. Many other countries followed, adapting HTA to their own institutional contexts. The field has since become a standard part of health policy infrastructure in high-income countries and is increasingly used in middle-income settings.
HTA is not a single method but a framework that integrates multiple disciplines. The major approaches differ in what they prioritize, how they measure value, and how they handle uncertainty and ethical considerations.
The foundational layer of HTA is the assessment of clinical effectiveness and safety. This approach, rooted in evidence-based medicine, asks: Does the technology produce better health outcomes than the alternatives? It relies on systematic reviews of randomized controlled trials (RCTs) when available, and on observational studies when RCTs are not feasible. The key method is meta-analysis, which statistically combines results from multiple studies to produce a pooled estimate of effect.
This approach is rigorous but has limits. RCTs may not reflect real-world populations or practice conditions. They are often short-term, while many technologies have long-term effects. And they typically measure efficacy (outcomes under ideal conditions) rather than effectiveness (outcomes in routine practice). HTA practitioners address these limits through pragmatic trials, registry data, and modeling, but the tension between internal validity and generalizability remains.
Economic evaluation is the most distinctive and controversial component of HTA. It asks whether a technology's health benefits justify its costs. The standard method is cost-utility analysis, which measures outcomes in quality-adjusted life years (QALYs). A QALY combines length of life and quality of life into a single metric, where one QALY equals one year of perfect health. The incremental cost-effectiveness ratio (ICER) compares the additional cost of a new technology to the additional QALYs it produces, relative to the next best alternative.
A technology is often considered cost-effective if its ICER falls below a threshold, typically expressed as cost per QALY gained. The most famous threshold is the UK's £20,000–£30,000 per QALY range used by NICE, though this is not a fixed rule and is debated. Other countries use different thresholds or avoid explicit numbers altogether.
This approach has been criticized on several grounds. The QALY metric is controversial: it may undervalue life extension for people with disabilities or chronic conditions, and it does not capture distributional concerns about who gains and who loses. The threshold itself is often based on historical precedent rather than rigorous evidence about what society is willing to pay. And the reliance on average cost-effectiveness ratios can obscure important variation across patient subgroups.
While cost-effectiveness analysis asks whether a technology is worth its cost, budget impact analysis asks whether a healthcare system can afford to adopt it. This is a separate question: a technology may be cost-effective but still impose an unmanageable financial burden if it is used by a large population or has a high unit cost. Budget impact models estimate the total expenditure change over a defined time horizon, typically 1–5 years, accounting for the eligible population, uptake rates, and offsets from reduced use of other services.
This approach is essential for decision-makers but is often less rigorous than cost-effectiveness analysis. It relies on assumptions about adoption rates and prices that are uncertain and may be influenced by negotiation. It also does not address whether the expenditure is worthwhile, only whether it is feasible.
HTA has increasingly incorporated ethical analysis and equity considerations. Early HTA focused narrowly on clinical and economic evidence, but critics argued that this ignored important value questions. For example, should a technology that extends life for a few months at very high cost be funded, even if it is not cost-effective? Should priority be given to technologies that benefit the worst-off, even if they produce fewer total QALYs?
These questions have led to the development of ethical frameworks for HTA, such as the "accountability for reasonableness" approach, which emphasizes transparency, relevance, and appeal mechanisms in decision-making. Some HTA bodies now explicitly consider equity impacts, for example by applying a higher cost-effectiveness threshold for technologies that treat rare diseases or that benefit disadvantaged populations. However, there is no consensus on how to weight equity against efficiency, and different countries make different trade-offs.
Beyond its analytical methods, HTA is also a social and institutional process. It involves stakeholders—patients, clinicians, industry, payers, and policymakers—in defining the scope of the assessment, interpreting the evidence, and making recommendations. This deliberative dimension recognizes that HTA decisions are not purely technical but involve value judgments that require democratic legitimacy.
Different HTA bodies handle this differently. Some, like NICE, have formal committees that include patient representatives and industry observers. Others rely more on expert panels or public consultations. The quality of deliberation depends on the transparency of the process, the diversity of perspectives included, and the clarity of the reasoning behind decisions.
HTA is now institutionalized in most high-income countries and is expanding in middle-income settings. The field is characterized by several durable tensions.
First, there is ongoing debate about the appropriate role of cost-effectiveness thresholds. Some argue that explicit thresholds are essential for accountability and consistency; others contend that they are arbitrary and that decisions should be made case by case. In practice, most HTA bodies use thresholds as reference points rather than rigid rules.
Second, the rise of expensive personalized medicines and gene therapies has challenged traditional HTA methods. These technologies often target small populations, making RCTs difficult and cost-effectiveness ratios very high. HTA bodies have responded with managed entry agreements, outcome-based payment schemes, and adaptive pathways, but these are experimental and raise their own governance challenges.
Third, the field is grappling with the integration of real-world evidence from electronic health records, registries, and wearable devices. This evidence can complement RCTs by providing data on long-term outcomes and diverse populations, but it also raises concerns about data quality, confounding, and privacy.
Fourth, there is growing attention to the social determinants of health and the broader impacts of technologies beyond clinical outcomes. Some HTA frameworks now include assessments of organizational impact, patient experience, and environmental sustainability, though these are not yet standard.
Finally, international collaboration is increasing through networks like the International Network of Agencies for Health Technology Assessment (INAHTA) and Health Technology Assessment International (HTAi). These efforts aim to share evidence, harmonize methods, and reduce duplication, but they must contend with differences in healthcare systems, values, and resources.
HTA remains a field in motion, shaped by the interplay of scientific evidence, economic constraints, ethical commitments, and political realities. Its core challenge—how to make wise choices about health technologies under uncertainty and scarcity—is unlikely to disappear.